Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer-Reference-Cited by-同舟云学术

Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer

Published:2001-08 Issue:2 Volume:58 Page:39-48
ISSN:0090-4295
Container-title:Urology
language:en
Short-container-title:Urology

Author:

Gleave Martin E,Miyake Hideaki,Zellweger Toby,Chi Kim,July Laura,Nelson Colleen,Rennie Paul

Publisher

Elsevier BV

Subject

Urology

Reference69 articles.

1. Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer;Denis;Cancer,1993

2. Management of hormone refractory prostate cancer;Oh;J Urol,1998

3. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer;Hudes;J Clin Oncol,1997

4. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer;Petrylak;J Clin Oncol,1999

5. Phase II trial of oral estramustine, oral etopside, and intravenous paclitaxel in hormone-refractory prostate cancer;Smith;J Clin Oncol,1999

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Decoding CLU (Clusterin): Conquering cancer treatment resistance and immunological barriers;International Immunopharmacology;2024-08

2. The Influence of Clusterin Glycosylation Variability on Selected Pathophysiological Processes in the Human Body;Oxidative Medicine and Cellular Longevity;2022-08-28

3. Apolipoproteins and cancer;Cancer Medicine;2019-10

4. The Multiple Roles and Therapeutic Potential of Molecular Chaperones in Prostate Cancer;Cancers;2019-08-16

5. New Opportunities for Targeting the Androgen Receptor in Prostate Cancer;Cold Spring Harbor Perspectives in Medicine;2018-03-12